Spent the last few weeks working on my latest essay. I have Spent years in healthcare. I’ve seen what happens when profit overshadows care. My new Medium post explains why we need robust public health solutions. Let’s fight for better outcomes—together! #Medsky #Oncology #HealthPolicy

The NCCN now recognizes ctDNA as a high-risk factor for recurrence in colon/rectal cancer and as a tool in Merkel cell carcinoma. While promising, routine use outside trials isn’t recommended yet. ctDNA’s role in personalized care is evolving! 🧬✨ #ColonCancer #Oncology #Medsky #Research

SEASONAL INFLUENZA SURGING. Please take care The 2024–2025 flu season — which has sickened an estimated 24 million Americans so far — is in full swing. However, there’s more to come before the season peaks www.today.com/health/cold-...

Personalized cancer vaccines are making waves! A new study shows a novel vaccine may be effective in stage III/IV clear cell RCC, offering hope for tailored treatment. Could this be the future of RCC care? Would anti vaxxers even accept this or still prefer Ivermectin?🧬✨ #Cancer #Oncology #Medsky

A new study suggests tracking tumor-infiltrating lymphocytes (TILs) during radiation therapy may offer insights into prognosis and guide personalized treatment in breast cancer. Monitoring immune responses could refine therapy strategies for better outcomes. 🧬✨ #BreastCancer #CancerResearch

With science falling under increasing attack, this medical historian is here to remind people of the power of #vaccines. THREAD🧵 Hard-hitting polio advert from 1958. In the first half of the 20th century, polio was the leading cause of death in children and young adults. 1/7

The FDA has granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for adults with unresectable or metastatic HER2-positive solid tumors who have received prior treatments . This approval offers new hope for patients with limited options. I love this drug! #BreastCancer #Oncology

I was set to enter a clinical trial in February. It's since been canceled. You are spot on with "cancer itself will not agree to such a delay." #Cansky

This week’s essay is inspired by the incredible support staff who make cancer care possible—and the tough reality of working without them. It takes a team to guide patients through their journey. Let’s not forget the value of every member of our healthcare Fellowship🧬✨ #Cancer #Oncology #Healthcare

This came out decades ago but remains a true and simple depiction of grief.

Aspirin after completion of standard adjuvant therapy for colorectal cancer (ASCOLT): a phase 3 international trial.’ This study found that aspirin 200 mg daily for 3 years was well tolerated but did not significantly improve disease-free survival 🧬✨ #Oncology #Cancer

Non-medical post: Onyx Storm dropped today, and my wife is already several chapters in. Every so often, I hear her say, ‘Just one more chapter,’ but we all know that’s book lover code for ‘leave snacks and back away slowly.’ It’s an art form, really. 📚😅 #OnyxStorm

My weekly essay is up, inspired by the countless moments this week spent calming anxious patients after early test results. Should oncologic results wait until the doctor’s appointment? Is instant access helping or hurting? Share your thoughts. 🧬✨ #Oncology #Hematology #Medsky

The FDA has approved sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer. This combo therapy tackles a previously ‘undruggable’ mutation, offering new hope for advanced cases. A major milestone in precision oncology! 🧬✨ #CancerResearch #OncologyNews

Phase II TROPION-Lung04 study indicate that datopotamab deruxtecan shows promising efficacy and a manageable safety profile in patients with advanced or metastatic non–small-cell lung cancer (NSCLC) who have been previously treated. ADCs are coming! #LungCancer #Oncology

My weekend essay inspired by a tough week of working with insurance. Two denials and one delayed treatment start. What is your experience with prior auths?

Always good reminder that’s where there is a will there is a way. *It also blows my mind that research funding for pediatric cancer is on chopping block with this new Congress. This is money well spent

This study suggests that a negative PSMA PET scan can help avoid unnecessary pelvic lymph node dissection in intermediate-risk prostate cancer patients, potentially reducing treatment complications without compromising outcomes. #ProstateCancer #MedicalImaging

Insurance denials and prior auths feel like trying to cross the Dead Marshes—every step forward is met with unseen obstacles dragging you down. Patients deserve a clear path to care, not to be lost in the bureaucracy. #Oncology #HealthcareFrustrations

It used to be the case that transplants were never done in cases of cancer (and for tragically practical reasons), so that it is now occasionally possible is a major step forwards: www.bbc.co.uk/news/article...

My first article. What is your opinion?

At #1 in our countdown: ‘Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors: Results From DESTINY-PanTumor02.’ This landmark trial expands the role of HER2-targeted therapy across multiple cancer types, marking a new frontier in precision medicine. 🧬✨ #OncologyPapers2024

At #2 in our countdown: ‘Long-Term Results of Organ Preservation in Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy: The OPRA Trial.’ This study highlights a step forward in organ preservation, showing promising long-term outcomes with reduced treatment intensity. 🧬✨ #OncologyPapers2024

At #3 in our countdown: ‘Lorlatinib vs. Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From the CROWN Study.’ This study confirms lorlatinib’s superior efficacy, improving long-term survival and quality of life for patients with advanced ALK-positive NSCLC. 🧬✨ #OncologyPapers2024

At #4 in our countdown: ‘Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.’ Results from the Phase III ARANOTE trial show significant efficacy, setting a new standard for combination therapy. 🧬✨ #CancerResearch2024

At #5 in our countdown: ‘Exagamglogene Autotemcel for Severe Sickle Cell Disease.’ This groundbreaking study demonstrates that 97% of patients treated with exa-cel were free from vaso-occlusive crises for at least 12 months, marking a significant advancement in gene therapy for sickle cell disease.

Exciting news! We’re counting down the top 5 most popular oncology papers of 2024Join me each as we explore the breakthroughs shaping cancer care. (Will add LOTR) doing for each of them From precision medicine to cutting-edge therapies, let’s dive into the science. 🧬✨ #TopOncologyPapers #2024Review

🩸 Liquid biopsy technology for detecting minimal residual disease (MRD) in lung cancer shows great promise, but is it ready for prime time? As we refine its accuracy and clinical utility, this tool could revolutionize early intervention and personalized care. #LungCancer #LiquidBiopsy

Another Lung Cancer Update: FDA approves ensartinib for ALK+ NSCLC based on eXALT3 trial results: improved PFS (25.8m vs 12.7m, HR 0.56) and CNS response (64% vs 21%) compared to crizotinib, but no OS difference. Cost may limit its use. #LungCancer #Oncology

The FDA has granted Breakthrough Therapy Designation to sacituzumab govitecan (Trodelvy) for adults with extensive-stage small cell lung cancer (ES-SCLC) progressing after platinum-based chemotherapy, highlighting its potential as a promising second-line treatment. #LungCancer #CancerResearch

Both #ASCO #NCCN describe challenges in treating renal cell carcinoma (RCC) post-first-line immunotherapy remain. Second-line options, like VEGF inhibitors and newer combinations, show promise, but optimizing sequencing and resistance management is critical. #KidneyCancer #Oncology

At #SABCS24, the SUPREMO trial reports that post-mastectomy chest wall irradiation offers no survival benefit for most intermediate-risk breast cancer patients, suggesting many can safely forgo this treatment. #BreastCancer #CancerResearch

At #ASH24, the IMMagine-1 trial presented promising results for anitocabtagene autoleucel (anti-BCMA CAR T-cell therapy) in relapsed/refractory multiple myeloma, showing high response rates in heavily pretreated patients. #MultipleMyeloma #CancerResearch

(Cancer News Update): “The PADMA study presented at #SABCS24 reveals that combining palbociclib with endocrine therapy outperforms chemotherapy in high-risk HR+/HER2- metastatic breast cancer, offering a more effective and less toxic treatment option. #BreastCancer #CancerResearch #PADMA

1/2: Big news from the San Antonio Breast Cancer Symposium: Some early-stage breast cancer patients may safely skip lymph node removal without compromising outcomes. This could mean fewer side effects and better quality of life. #BreastCancer #CancerUpdates apnews.com/article/brea...

In Middle-earth terms, osimertinib is like the black arrow of Bard the Bowman—crafted for a singular purpose, to take down Smaug (the EGFR mutation). Just as Smaug’s armor had a weak spot, cancer driven by EGFR mutations has vulnerabilities that these therapies exploit. Precision is everything. 🏹

Big news in lung cancer treatment: Targeted therapies are making huge strides. For patients with EGFR mutations, drugs like osimertinib are extending survival and improving quality of life. This is precision medicine at its finest—designed to attack the cancer without harming healthy cells

One does not simply fight cancer without the right tools. Whether it’s cutting-edge treatments or knowledge that shines brighter than the light of Eärendil, I’m here to guide you through it all. Follow along as we conquer the darkness—one post and one laugh at a time. 🛡️✨ #CancerAwareness #LOTRNerd